Pfizer Inc PFE

$29.88 -0.91 (-2.96%)

Valuation

Market cap
175,492,960,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.84
P/E (forward)
10.19
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
53,051,021
Avg volume
33,274,012
Day's range
$29.85 – $31.44
Shares out
5,699,674,000
Stochastic %K
30%
Beta
0.31
Analysts
Hold
Price target
$29.70

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

biolover Nov 6, 2:14 AM
$BBIO is going against $PFE and doing well $TGTX against Roche .:: and others For $VKTX is much easier as consumer driven.. news spread like 🔥 . If they offer something $50 cheaper then $LLY they could take 20% of Lilly business. They will be limited by supply and this is why BI cut deals with 4 sources. I can’t see Lilly just watching at the end. ..
1 replies
Typecheck Nov 6, 1:33 AM
$PFE PFE is a corporate bond pretending to be a stock. Trade accordingly.
1 replies
Cogsey Nov 6, 1:21 AM
$PFE dividend correction
0 replies
BlowMe69 Nov 6, 1:13 AM
$PFE Yank Me
0 replies
PFElinepfrenzy1990 Nov 6, 1:12 AM
$PFE - Don’t worry about the overnight drop. It’s the dividend 😀
1 replies
GTA_Terminal Nov 6, 1:07 AM
Unusual options activity in $PFE, almost all of it calls. $PFE is down 3.0% today, and the options money leaned calls. Chasing it or hedging it? Several of the big contracts traded above open interest, which points to new positions, not traders closing old ones. Look up any stock's options flow and dark pools on the GTA Terminal, free for 14 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PFE&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PFE Read the full article for the full details: https://globaltradersacademy.com/articles/pfizer-pfe-institutional-flow-at-the-close-thursday-nov-5-100-of-the-options?utm_source=stocktwits&utm_medium=social
0 replies
garyho02 Nov 5, 11:25 PM
$PFE enormous drop in the market today. We held up okay
2 replies
Ro_Patel Nov 5, 11:13 PM
$AAOI has wiped out ~80% of its peak market value (from the May 2026 high near $234). The derating feels reminiscent of $PFE after COVID vaccine revenues peaked — except Pfizer’s collapse came after the demand cliff was already visible. Is peak data-center buildout visible????
0 replies